

Eurofins successfully places EUR 500m new Euro bond

21 January 2015

Eurofins Scientific (ERF FP, unrated), the global leader in bioanalytical testing, announces that it has successfully raised EUR 500m in its second senior unsecured Euro bond public issuance. The bonds have a seven-year maturity (due 27 January 2022) and will bear an annual coupon of 2.25% (ACT/ACT). The issue was more than three times over-subscribed.

Eurofins intends to use the proceeds of the offering for general corporate purposes as part of its mid-term development plan with the objective to achieve revenues of EUR 2bn by 2017, as well as to secure its longer-term leading position in the markets where it is active. In addition, part of the proceeds is planned for balance sheet optimization to lengthen the average maturity of its debt whilst reducing its average cost of capital.

Comment from Dr. Gilles Martin, Eurofins CEO: *"I am pleased with the strong success of our second public bond issuance, and the confidence that investors continue to put into Eurofins. Whilst we have decided to take advantage of the current favourable interest rates in the market, and secure and diversify long-term funding, we intend to maintain a strong balance sheet structure and our disciplined approach to acquisitions."*

HSBC acted as global coordinator and joint bookrunner for the transaction, with BNP Paribas and SG CIB as joint bookrunners.

The bonds will be listed, from their issue date (27 January 2015), on the regulated market of the Luxembourg stock exchange (ISIN XS1174211471). The bonds are not registered under the US Securities Act of 1933 as amended (the "Securities Act"), and may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration.

For more information please visit <http://www.eurofins.com> or contact:

Eurofins Investor Relations
Phone: + 32 2 769 7383
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.

With over 16,000 staff in more than 200 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of

biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.